Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
about
MAO-inhibitors in Parkinson's DiseaseOne for All? Hitting Multiple Alzheimer's Disease Targets with One DrugDrug Development in Alzheimer's Disease: The Contribution of PET and SPECTInteractions of Monoamine Oxidases with the Antiepileptic Drug Zonisamide: Specificity of Inhibition and Structure of the Human Monoamine Oxidase B ComplexMolecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Antidiabetes DrugsI1 imidazoline receptor: novel potential cytoprotective target of TVP1022, the S-enantiomer of rasagilineFrom single target to multitarget/network therapeutics in Alzheimer's therapyHigh throughput screening to identify natural human monoamine oxidase B inhibitorsComparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growth in vivo.Nicotine as a potential neuroprotective agent for Parkinson's disease.Predicting and characterizing selective multiple drug treatments for metabolic diseases and cancer.Metabolite profile resulting from the activation/inactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 2-methyltetrahydro-β-carboline by oxidative enzymes.Molecular targets of the multifunctional iron-chelating drug, M30, in the brains of mouse models of type 2 diabetes mellitusNew approaches to treating Alzheimer's diseasePast, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases.From omics to drug metabolism and high content screen of natural product in zebrafish: a new model for discovery of neuroactive compound.Catecholamines and Neurodegeneration in Parkinson's Disease-From Diagnostic Marker to Aggregations of α-Synuclein.Involvement of Bcl-2-associated athanogene (BAG)-family proteins in the neuroprotection by rasagiline.In Vitro and in Vivo Neuroprotective Effects of Walnut (Juglandis Semen) in Models of Parkinson's DiseaseMultisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brainNeuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease.A Peroxidase-linked Spectrophotometric Assay for the Detection of Monoamine Oxidase Inhibitors.Motor phenotype and magnetic resonance measures of basal ganglia iron levels in Parkinson's disease.The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's diseaseIron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim.Gene expression profiling and therapeutic interventions in neurodegenerative diseases: a comprehensive study on potentiality and limits.Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders.Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease.Promise of neurorestoration and mitochondrial biogenesis in Parkinson's disease with multi target drugs: an alternative to stem cell therapy.Monoamine oxidase A and B substrates: probing the pathway for drug development.Effects of novel neuroprotective and neurorestorative multifunctional drugs on iron chelation and glucose metabolism.Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targets.Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond.Rational drug discovery design approaches for treating Parkinson's disease.Modern treatment in Parkinson's disease, a personal approach.Mitochondrial permeability transition pore: a promising target for the treatment of Parkinson's disease.Multitarget strategies in Alzheimer's disease: benefits and challenges on the road to therapeutics.Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline.
P2860
Q24629770-75A448F5-B9E5-4332-9DE8-4F6D18984FC4Q26747572-1B4CC9C2-3EA2-4E19-AC0C-758F19594810Q26749755-3D8F750C-9F58-48D9-85DE-3C420EC7AFFDQ27666365-E6280CFD-3B7C-4064-B72B-381601C5186CQ27676922-A454ADFE-2F74-4644-A039-F6EACA315709Q28485219-CE14B598-231C-43FB-B31B-BF648F1E64E4Q28658200-9EB7F925-FC53-451D-9B3B-BF181B57D7CAQ31083774-D70A3C09-327F-478F-B3E8-258035E36F44Q34269401-52F0C5E8-9DA4-4F63-BDE2-66B4F8AAC31EQ34281003-448476BF-90C4-4BE6-98D7-C8377BBE1F96Q34397561-301887EC-7879-46E6-B543-10034266476BQ34655711-45048655-7934-4E3B-B514-421192BE3EBBQ34914164-921C8C8C-F8DF-4FEF-BE00-DFF97C8E2385Q35081742-E00F128A-B620-4147-88C0-F9EA2F35F6A7Q35489240-3D2EF0A1-7FE4-470D-A713-E426A6C9BA78Q35958359-3C31137B-6E4D-48BF-B214-9316A9CFCF05Q36167799-931ECF8C-95DD-46E8-B24F-14E0C784B752Q36335146-FC5B8145-C942-4C82-A5F2-9B414BC49BA9Q36411750-FB65AA48-7A00-4A93-993C-9E461943000EQ36512635-24A0842F-047E-4BC6-84D8-88915FAFC84FQ36851713-E7A11FF4-8B8F-40AF-88D4-C475BDB5723BQ37005143-23662624-98EB-4978-A930-09F4D412DBA6Q37178189-6DECDEFC-9C40-4DE6-8403-526C717841BEQ37426208-90D51409-039A-4527-97DF-D2D9BF16069FQ37845675-D98EFF45-E075-4A8C-A9F2-7B20079BC0E8Q37848245-F32BAA61-10CF-45A2-9978-76F613509E0CQ37999105-CA063843-45F6-4D9E-B540-E7C91C7BD1FFQ38021661-113D9891-E068-4A66-BB8D-D73B5E417CE4Q38066606-24BDF0AC-742F-45CE-870C-9BB18E0303C0Q38134903-E1A4FE91-6C80-4293-BBE2-F39801DB401CQ38156161-8E3F86FB-8529-4AEB-90B7-16F52DCF445DQ38217505-C6959C97-51D9-488B-A164-5B069D4687E1Q38326678-0F4E088B-56C6-48C4-B553-2063AA342CFCQ38414169-A5BD78B2-65F2-4587-B356-AB69E1C923B6Q38447289-8BCDC39A-3C5D-4723-A164-DFA84CA57BD5Q38520864-87D7474F-925D-4928-B9E8-F10D11615887Q38570529-6B788C81-F5C4-46F2-9177-098E288DD24CQ38716156-DBFB0D77-CA3A-420B-8444-1FE991A1472EQ38881147-466E23F7-F353-4475-B30D-B3F1C9C11A65Q39694072-AD0FD084-B04E-4F64-9C61-4DF5A22BEE07
P2860
Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rasagiline: a novel anti-Parki ...... with neuroprotective activity.
@en
Rasagiline: a novel anti-Parki ...... with neuroprotective activity.
@nl
type
label
Rasagiline: a novel anti-Parki ...... with neuroprotective activity.
@en
Rasagiline: a novel anti-Parki ...... with neuroprotective activity.
@nl
prefLabel
Rasagiline: a novel anti-Parki ...... with neuroprotective activity.
@en
Rasagiline: a novel anti-Parki ...... with neuroprotective activity.
@nl
P2093
P1476
Rasagiline: a novel anti-Parki ...... with neuroprotective activity.
@en
P2093
Moussa B H Youdim
Orit Bar-Am
Orly Weinreb
Tamar Amit
P304
P356
10.1016/J.PNEUROBIO.2010.06.008
P577
2010-06-19T00:00:00Z